# ARP Pipeline Enhancement: Generative AI Continuum Integration
**Date:** 2026-05-11  
**Based on:** MDPI Pharmaceuticals 2026 (Generative AI Transitions) + Briefings in Bioinformatics 2026 (Boltz-2)  
**Goal:** Nature/Cell/Science-level research plan for FSP1/SLC7A11/DGAT1 triple ferroptosis platform

---

## Executive Summary

두 최신 논문의 인사이트를 통합하여 ARP Pipeline을 enhanced합니다:

| Paper | Key Insight | ARP Integration |
|-------|-------------|-----------------|
| **Pharmaceuticals 2026** | Rentosertib: AI-discovered target → Phase IIa success | FSP1 program template |
| **Pharmaceuticals 2026** | Generative AI Continuum = self-improving cycle | Pipeline architecture |
| **Briefings in Bioinformatics 2026** | Boltz-2 affinity prediction for aptamer/drug | boltz2_client.py enhancement |

**North star:** Rentosertib ($150K, 18 months, Phase IIa success)를 FSP1 program에 적용

---

## 1. Reference Case: Rentosertib (Rentosertib Pathway)

### 1.1 Rentosertib Success Story

| Stage | Traditional | AI-Driven (Rentosertib) |
|-------|-------------|------------------------|
| Target ID | SILAC, GWAS | Multi-omics + GNN + NLP |
| Timeline | 10-15 years | ~18 months |
| Cost | >$2 billion | ~$150K (self-reported) |
| Phase I success | <10% | Phase IIa ✅ |

### 1.2 Rentosertib Mechanism

```
Multi-Omics data (patient tissues + literature)
           ↓
    GNN + Deep Learning
           ↓
    TNIK target identification
           ↓
    Generative chemistry engine (de novo design)
           ↓
    Rentosertib (small molecule inhibitor)
           ↓
    Phase IIa: +98.4 mL FVC vs placebo ✅
```

### 1.3 FSP1 Program as Rentosertib Analog

| Element | Rentosertib/TNIK | FSP1 Program |
|---------|------------------|--------------|
| **Target** | TNIK (first-in-class) | FSP1 (first-in-class) |
| **Indication** | IPF (fibrotic disease) | NSCLC (KEAP1/STK11-altered) |
| **AI target ID** | Multi-omics + literature | TCGA/GEO + SLC7A11 bioinformatics |
| **AI molecular design** | Generative chemistry | Boltz-2 + FSEN1/viFSP1 leads |
| **Validation** | Phase IIa FVC | TGI >50% in vivo |
| **Timeline target** | 18 months to preclinical | 30-42 months to IND |
| **Cost target** | $150K | $15-35M |

---

## 2. Generative AI Continuum for ARP

### 2.1 Framework

```
┌────────────────────────────────────────────────────────────────────┐
│                    GENERATIVE AI CONTINUUM                          │
├────────────────────────────────────────────────────────────────────┤
│                                                                    │
│  ┌───────────┐    ┌──────────────┐    ┌──────────────┐    ┌─────┐ │
│  │Multi-Omics│───▶│  Target ID   │───▶│  Molecular   │───▶│Clinical│ │
│  │  Data     │    │  (FSP1/SLC)  │    │   Design     │    │Trial │ │
│  └───────────┘    └──────────────┘    └──────────────┘    └─────┘ │
│       ▲                ▲                   ▲                   │
│       │                │                   │                   │
│       │                │                   │                   │
│       └────────────────┴───────────────────┴───────────────────┘   │
│                    Self-Improving Cycle                             │
└────────────────────────────────────────────────────────────────────┘
```

### 2.2 ARP Implementation

| Stage | Components | Tools |
|--------|-----------|-------|
| **Multi-Omics** | TCGA-LUAD, GEO, SLC7A11 bioinformatics | Python, scanpy |
| **Target ID** | FSP1, SLC7A11, DGAT1, ACLY/ACSS2 | arp_orchestrator.py |
| **Molecular Design** | FSEN1/viFSP1 leads, DGAT1-LUNG | boltz2_client.py, LinkLlama |
| **Binding Prediction** | Affinity estimation | Boltz-2 (NIM/local) |
| **Biomarker** | ML Biomarker Strategy (FRS, CBMS) | scikit-learn, XGBoost |
| **Clinical** | Trial design | LLM-assisted protocol |

---

## 3. ARP Pipeline Architecture (Enhanced)

### 3.1 Self-Improving Cycle

```
Step 1: Multi-Omics Input
├── TCGA-LUAD (RNA-seq)
├── GEO cohorts (GSE31210, etc.)
├── SLC7A11 bioinformatics (Larry report)
└── Literature (Nature 2025, PNAS 2025)

Step 2: AI-Driven Target Discovery
├── FSP1 (ferroptosis defense)
├── SLC7A11 (GSH/GPX4 axis)
├── DGAT1 (lipid droplets)
└── ACLY/ACSS2 (acetyl-CoA, MASH)

Step 3: Generative Molecular Design
├── FSEN1-like scaffolds
├── viFSP1-like scaffolds
├── DGAT1-LUNG modifications
└── ACLY/ACSS2 dual inhibitors

Step 4: Binding Affinity Prediction
├── Boltz-2 (affinity module)
├── AlphaFold3 (structure)
└── MD simulations (stability)

Step 5: ML Biomarker Stratification
├── FRS (Ferroptosis Regulation Score)
├── NRF2 Activity Score
├── Triple Combo Score (TFCS)
├── TME Score (TMS)
└── Composite Biomarker Score (CBMS)

Step 6: Clinical Trial Design
├── Patient selection (CBMS-based)
├── Combination (RT, ICI, Chemo)
└── Endpoints (ORR, PFS, PD biomarkers)

Step 7: Feedback Loop
└── Clinical data → Update models → Refine targets
```

### 3.2 Technology Stack

| Layer | Tools | Purpose |
|-------|-------|---------|
| **Data** | Python, scanpy, pandas | Multi-omics processing |
| **Target ID** | arp_orchestrator.py | Playbook-based discovery |
| **Molecular Design** | Boltz-2, LinkLlama | Structure + affinity |
| **ML Biomarkers** | scikit-learn, XGBoost, PyTorch | Patient stratification |
| **Visualization** | matplotlib, seaborn, plotly | Results |
| **Version Control** | Git + GitHub | Reproducibility |

---

## 4. Target Programs (3 Parallel Tracks)

### 4.1 NSCLC: FSP1 Inhibitor

| Element | Details |
|---------|---------|
| **Target** | FSP1 (AIFM2) |
| **Indication** | KEAP1/STK11/NFE2L2-altered LUAD |
| **Rationale** | Ferroptosis defense → inhibition = tumor selective death |
| **Reference** | Nature 2025: 80% tumor reduction (mouse) |
| **Chemical series** | FSEN1, viFSP1, iFSP1, icFSP1 |
| **Timeline** | 33-42 months to IND |
| **Cost** | $15-35M |

### 4.2 NSCLC: SLC7A11 Inhibitor (Already Validated)

| Element | Details |
|---------|---------|
| **Target** | SLC7A11 (system xc-) |
| **Indication** | LUAD (EGFR+ enriched) |
| **Rationale** | GPX4 negative correlation → dual inhibition synergy |
| **Reference** | Larry bioinformatics (TCGA + GEO) |
| **Clinical hook** | EGFR-TKI resistance |
| **Drug repurposing** | Sulfasalazine (FDA-approved) |

### 4.3 MASH: Dual ACLY/ACSS2 Inhibitor

| Element | Details |
|---------|---------|
| **Target** | ACLY + ACSS2 |
| **Indication** | MASH F2-F3 |
| **Rationale** | Acetyl-CoA bypass blockade |
| **Reference** | Cell Metabolism 2026 (EVT0185) |
| **Timeline** | 30-39 months to IND |
| **Cost** | $12-28M |

---

## 5. Rentosertib-Style Pipeline: Step-by-Step

### Phase 1: Target Discovery (Q2-Q3 2026)

```python
# Multi-omics integration
from scanpy import AnnData
import pandas as pd

# TCGA-LUAD + GEO + SLC7A11 data
data = load_multiomics([
    "TCGA-LUAD_RNAseq",
    "GSE31210",
    "SLC7A11_bioinformatics"
])

# FSP1/SLC7A11/DGAT1 expression analysis
targets = ["FSP1", "SLC7A11", "DGAT1", "ACLY", "ACSS2"]
expression_df = data.query_genes(targets)

# Ferroptosis pathway scoring
from sklearn.preprocessing import StandardScaler
scaler = StandardScaler()
ferroptosis_score = scaler.fit_transform(expression_df)
```

### Phase 2: Generative Chemistry (Q3-Q4 2026)

```python
# Boltz-2 for structure prediction
from boltz2_client import Boltz2Client

client = Boltz2Client(mode="local")  # or "nim"

# FSP1 + FSEN1-like compound
structure = client.predict(
    protein_sequence="FSP1_sequence",
    ligand_smiles="FSEN1_analog_SMILES",
    task="docking"
)

# Affinity prediction
affinity = client.predict_affinity(
    protein="FSP1",
    ligand="FSEN1_analog"
)
```

### Phase 3: ML Biomarker (Q4 2026)

```python
# Ferroptosis Regulation Score (FRS)
from sklearn.linear_model import LassoCV
from xgboost import XGBClassifier

# 24-gene ferroptosis panel
frs_model = LassoCV(cv=5)
frs_model.fit(X_train, y_ferroptosis_sensitivity)

# Triple Combo Score (TFCS)
tfcs_model = XGBClassifier()
tfcs_model.fit(X_features, y_response)

# Composite Biomarker Score (CBMS)
CBMS = 0.30 * FRS + 0.25 * NRF2 + 0.25 * TMS + 0.20 * TFCS
```

### Phase 4: IND-Enabling (2027)

| Study | Duration | Purpose |
|-------|----------|---------|
| CMC | 3-6 months | Compound synthesis |
| ADMET | 6-9 months | Absorption, distribution, metabolism |
| Safety (TOX) | 9-12 months | In vivo toxicity |
| PK/PD | 6-9 months | Exposure-response |

---

## 6. Comparison: Traditional vs ARP AI-Driven

| Factor | Traditional Pharma | ARP AI-Driven |
|--------|-------------------|---------------|
| Target ID | SILAC, GWAS (years) | Multi-omics + literature (weeks) |
| Molecular design | HTS of 1M+ compounds | Generative AI + virtual screening |
| Lead optimization | Iterative chemistry (2-3 years) | Structure-based design + ML (months) |
| Binding prediction | Experimental assaying | Boltz-2 + MD (days) |
| Biomarker | Single biomarker | Composite ML score (CBMS) |
| Timeline | 10-15 years | 3-4 years (projected) |
| Cost | >$2B | $15-35M (preclinical) |
| Clinical attrition | <10% reach approval | Optimized via biomarkers |

---

## 7. Competitive Positioning

### 7.1 Market Opportunity

| Program | Market | Unmet Need | Competition |
|---------|--------|-----------|-------------|
| **FSP1i (NSCLC)** | $40B+ | No metabolism-directed drug | First-in-class |
| **SLC7A11i** | $40B+ | EGFR-TKI resistance | Sulfasalazine off-patent |
| **ACLY/ACSS2i (MASH)** | $35B+ | F4/cirrhosis untreatable | First-in-class |

### 7.2 IP Strategy

| Element | Protection |
|---------|------------|
| **FSP1 inhibitors** | New chemical entities (NCEs) |
| **FSEN1 analogs** | Patentable compositions |
| **Biomarker panel** | CBMS + companion diagnostic |
| **Combination** | FSP1i + RT/ICI protocol |

### 7.3 Partnership/Exit

| Stage | Value | Partner Type |
|-------|-------|--------------|
| Lead optimization | $50-100M | Co-development |
| IND filing | $100-200M | Series A or partnership |
| Phase I success | $300-500M | Valuation uplift |
| Phase IIa | $500M-1B | Acquisition/royalty |

---

## 8. Key References

1. **Rentosertib**: AI-designed drug, Phase IIa success (IPF)
   - Source: Pharmaceuticals 2026
   
2. **FSP1**: Nature 2025 (80% tumor reduction), PNAS 2025 (FSEN1 co-crystal)
   
3. **Boltz-2**: Affinity prediction module for protein-ligand binding
   - Source: Briefings in Bioinformatics 2026
   
4. **SLC7A11**: LUAD bioinformatics (Larry report)
   - TCGA + GEO validation, HR=1.52, p=0.021
   
5. **ACLY/ACSS2**: Cell Metabolism 2026 (EVT0185)
   - Dual inhibition in MASH mouse models

---

## 9. Timeline

```
2026 Q2-Q3   Target Discovery (Multi-omics + literature)
2026 Q3-Q4   Generative Chemistry (Boltz-2 + leads)
2026 Q4      ML Biomarker Development
2027 Q1-Q2   Lead Optimization
2027 Q3-Q4   IND-Enabling Studies
2028 Q1      IND Filing
2028 Q4      Phase I Start
```

---

## 12. PK/PD Automation: PD Union Integration

### 12.1 PD Union Framework

**Reference:** Du et al. 2026, medRxiv preprint (doi:10.64898/2026.05.05.26352278)

**Problem:** Traditional PD modeling requires manual model selection, repeated equation rewriting, and empirical parameter adjustment.

**Solution:** Unified mechanistic skeleton + ML-assisted structure identification

### 12.2 PD Union Architecture

```
Input: Population PK/PD time series
    ↓
Unified Mechanistic Skeleton
├── Absorption/Exposure module
├── Receptor module
├── Delay module
├── Primary PD function
├── Feedback module
├── Circadian modulation
├── Disease state module
└── Second PD axis modules
    ↓
AI-Assisted Structure Identification
├── ML pattern recognition
└── Candidate structure ranking
    ↓
Parameter Fitting (L-BFGS-B)
    ↓
Output: Mechanistic PD model (interpretable)
```

### 12.3 Performance

| Metric | Value |
|--------|-------|
| Structure identification (NRMSE) | 0.7600 |
| Macro-average F1 | 0.6307 |
| Parameter fitting NRMSE (mean) | 0.146 |
| Parameter fitting NRMSE (median) | 0.117 |
| Literature validation | 14/15 outperformed original |

### 12.4 ARP PK/PD Integration

| Application | Use Case |
|-------------|----------|
| **FSP1i PK/PD** | Predict human dose from mouse PK |
| **Biomarker modeling** | FRS, CBMS time-course |
| **Clinical trial simulation** | Virtual patient PK/PD |
| **Drug combination** | Additive/synergistic PD modeling |
| **ACLY/ACSS2i** | Liver exposure-PD relationship |

### 12.5 Implementation Concept

```python
# PD Union for ARP Pipeline
class ARPPKPDModel:
    """Automated PK/PD modeling for ARP compounds"""
    
    def __init__(self, compound, target):
        self.compound = compound
        self.target = target
        self.skeleton = UnifiedSkeleton()
        
    def fit(self, time_series_data):
        # Step 1: ML-assisted structure identification
        structure = self.skeleton.identify(
            time_series_data,
            ml_assisted=True
        )
        
        # Step 2: Parameter optimization
        params = optimize_params(
            structure,
            time_series_data,
            method='L-BFGS-B'
        )
        
        # Step 3: Model validation
        diagnostics = validate_model(params)
        
        return MechanisticModel(structure, params, diagnostics)
    
    def predict_human_dose(self, animal_pk):
        """Allometric scaling + PD Union model"""
        human_pk = allometric_scale(animal_pk)
        return self.model.predict(human_pk)
```

### 12.6 Integration with Existing Pipeline

```
ARP Pipeline Flow:
│
├── Target ID (arp_orchestrator.py)
│
├── Molecular Design (boltz2_client.py)
│
├── In vitro assay → IC50, selectivity
│
├── In vivo PK/PD (mouse models)
│   ↓
│   PD Union Model (automated)
│   ├── Structure identification
│   ├── Parameter fitting
│   └── Model validation
│
├── ML Biomarker (ML_BIOMARKER_STRATEGY)
│   ├── FRS
│   ├── NRF2 score
│   ├── TMS
│   └── CBMS
│
└── Clinical Trial Design
    ├── Patient stratification
    ├── Dose prediction
    └── PK/PD simulation
```

---

## 13. Complete Technology Stack

| Layer | Tools | Purpose |
|-------|-------|---------|
| **Data** | Python, scanpy, pandas, numpy | Multi-omics processing |
| **Target ID** | arp_orchestrator.py | Playbook-based discovery |
| **Molecular Design** | Boltz-2, LinkLlama | Structure + affinity |
| **Binding Prediction** | Boltz-2 affinity module | Protein-ligand docking |
| **ML Biomarkers** | scikit-learn, XGBoost, PyTorch | Patient stratification |
| **PK/PD Modeling** | PD Union framework | Dose prediction |
| **Visualization** | matplotlib, seaborn, plotly | Results |
| **Version Control** | Git + GitHub | Reproducibility |

---

## 14. Key References

1. **Pharmaceuticals 2026**: Generative AI in drug discovery (Rentosertib pathway)
2. **Briefings in Bioinformatics 2026**: Boltz-2 benchmarking
3. **medRxiv 2026**: PD Union automated PK/PD modeling
4. **Nature 2025**: FSP1 in lung cancer (80% tumor reduction)
5. **PNAS 2025**: FSEN1 co-crystal structure
6. **Cell Metabolism 2026**: EVT0185 dual ACLY/ACSS2 in MASH
7. **TCGA/GEO**: SLC7A11 LUAD bioinformatics (Larry report)

---

*Report generated: 2026-05-11 | ARP v24*
*Enhanced: PD Union PK/PD automation integration*